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Purpose: To compare the dose uniformity of difluprednate ophthalmic emulsion 0.05% 
(Durezol®) with both branded and generic prednisolone acetate ophthalmic suspension 1% 
under different simulated patient usage conditions.
Methods: Drug concentrations of difluprednate emulsion, branded prednisolone acetate 
suspension (Pred Forte®) and generic prednisolone acetate suspension following three storage 
conditions (upright, then shaken; upright, not shaken; inverted, not shaken) were analyzed by 
high performance liquid chromatography assay and results were reported as percent of declared 
concentration. Two drops were dispensed every four hours four times daily.
Results: Regardless of bottle orientation and shaking, all difluprednate emulsion concentrations 
at each time point analyzed were within 15% of declared concentration. Both branded and 
generic prednisolone acetate suspension concentrations varied substantially throughout the 
study. For the bottle stored upright and not shaken, 46% of the branded concentrations were 
not within 15% of declared concentration; for the bottle stored upright and shaken prior to use, 
60% failed to meet this criterion. None of the branded concentrations from the inverted and not 
shaken bottle was within 15% of declared concentration. Generic prednisolone concentrations 
demonstrated the poorest dose uniformity, with 96% of the concentrations from the inverted 
and not shaken bottle not within 15% of declared concentration; 94% of the concentrations 
from the upright and shaken bottle and 87% from the upright and not shaken bottle similarly 
failed to meet this criterion.
Conclusions: Dose uniformity of Durezol emulsion was predictable in all simulated patient 
usage conditions, whereas the drop concentrations of Pred Forte and generic prednisolone acetate 
suspensions were highly variable throughout the study. Drop concentrations are more predictable 
with Durezol emulsion than with either prednisolone acetate suspension.
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Introduction
The dose uniformity of any ophthalmic medication is critically dependent on the 
homogeneity of the formulation. Most topical ophthalmic preparations containing 
lipid-soluble and aqueous components are suspensions, in which the active drug is 
suspended in an aqueous vehicle. Homogeneity is a concern for suspensions because 
sedimentation and aggregation occurs upon storage of the medication.1 Because of a 
suspension’s tendency to settle over time, suspensions must be shaken prior to use in 
order to redisperse the drug throughout the contents of the bottle. The need for shaking Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
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to achieve dose uniformity raises several potential concerns. 
First, the type, intensity, and duration of shaking behavior 
vary among people, and no studies have identified the shaking 
characteristics required for optimal redispersibility.2 Second, 
in a study of corticosteroid preparations, Apt et al determined 
that patient compliance with shaking instructions was only 
37%.3 Third, even with “optimal” shaking, suspensions 
may potentially have poor homogeneity due to formulation 
issues with particle size, caking, and agglomeration. Each 
of these issues may contribute to a lack of dose uniformity, 
which produces the potential for decreased efficacy with 
lower-than-expected dosing or increased safety concerns 
with higher-than-expected dosing.
Technologic advances have now provided ophthalmic 
preparations consisting of oil in water emulsions, with the drug 
molecule dissolved in the oil phase and aqueous-compatible 
surfactants providing emulsion stability, obviating the need 
for shaking prior to use. Thus, emulsion formulations have 
improved dose uniformity compared with suspensions. 
Ophthalmic emulsions were first introduced nearly a decade 
ago, with the commercial availability of two dry eye products, 
ie, over-the-counter (OTC) Refresh Endura® (Allergan, Inc., 
Irvine, CA) and prescription formula Restasis® (Allergan, 
Inc.). Since that time, another artificial tear product with a 
lipid emulsion formulation, the OTC Soothe® XP Emollient 
eye drops (Bausch and Lomb, Rochester, NY), has been 
introduced. Difluprednate ophthalmic emulsion 0.05% 
(Durezol®, Alcon Laboratories, Inc., Fort Worth, TX) is the 
only other ophthalmic lipid emulsion commercially available 
in the US. This corticosteroid was approved by the US Food 
and Drug Administration in 2008 for the treatment of pain 
and inflammation associated with ocular surgery.4
In order to verify the expected dose uniformity of the 
difluprednate emulsion, the concentration of difluprednate 
was measured under varying simulated patient conditions. 
It was also compared with two active controls, branded 
prednisolone acetate ophthalmic suspension 1% (Pred Forte®, 
Allergan, Inc., Irvine, CA), one of the most commonly 
used formulations of ophthalmic prednisolone in the US, 
and generic prednisolone acetate ophthalmic suspension 
1%. Prednisolone acetate is indicated for the treatment of 
steroid-responsive inflammation of the palpebral and bulbar 
conjunctiva, cornea, and anterior segment of the globe.5
Methods
Test articles
Commercially available difluprednate ophthalmic emulsion 
0.05% (Durezol), branded prednisolone acetate ophthalmic 
suspension 1% (Pred Forte), and generic prednisolone acetate 
ophthalmic suspension 1% (Falcon Pharmaceuticals Ltd) in 
their originally manufactured containers were evaluated in 
this study. Five mL of difluprednate was contained in a 5 mL 
nominal volume bottle and 5 mL each of branded and generic 
prednisolone acetate was contained in 10 mL bottles.
Study procedure
This study evaluated the effects of bottle orientation during 
storage and the presence or absence of shaking on the 
uniformity of dispensed drops. Three bottles of each test 
article were stored in a defined orientation for 12 hours, ie, 
two bottles of each test article were stored upright and one 
each was stored inverted. Following storage, one of the two 
upright bottles of each test article was shaken for five seconds 
using a wrist-action mechanical shaker at six cycles/sec, with 
an amplitude of 0.7 cm (Table 1). After shaking the two test 
article bottles, two drops of all nine bottles were dispensed 
into a tared glass vial. The drug concentration of the drops 
was analyzed by high performance liquid chromatography 
(HPLC), and results were reported as percent of declared 
concentration. The assay for determining difluprednate 
concentration was a specific, stability-indicating, normal-
phase HPLC method. The procedure used gradient elution 
and ultraviolet detection. The assay method in the monograph 
for prednisolone acetate ophthalmic suspension in the US 
Pharmacopeia was used for determining prednisolone acetate 
concentration. A slight modification in sample preparation 
was made and validated to account for the small sample 
size used in this study. In all cases, HPLC instrumentation 
from Waters Corporation (Milford, MA) was utilized. The 
dispensing protocol was repeated three times at four-hour 
intervals each day to simulate four times daily patient dosing. 
On days 0, 5, 10, and 15, the drug concentrations from each 
of the four time points were analyzed. On the other days, data 
from the first and fourth time points were analyzed.
Table 1 Study design evaluating the effect on ophthalmic steroid 
dose uniformity of varying simulated patient usage conditions, 
specifically bottle storage orientation and shaking
Test article Storage orientation Shaking
Pred Forte® Upright no
Upright Yes
inverted no
Durezol® Upright no
Upright Yes
inverted no
generic prednisolone Upright no
Upright Yes
inverted noClinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Results
The dose uniformity of all three steroid preparations after 
upright bottle storage and no shaking prior to dispensing is 
shown in Figure 1. The percentage of declared concentration 
of the difluprednate emulsion was near 100% at 97.6% (40/41) 
of the data points for this test condition. The percentage of 
declared concentration of the branded prednisolone acetate 
suspension was more variable over time, ranging from 20.5% 
to 181.4%. At day 0, prednisolone concentrations were 
greater than the declared concentration, but then dropped 
below declared concentration and did not consistently reach 
concentrations greater than 100% until day 5. Concentrations 
remained primarily above 100% through day 7, then were near 
or below 100% through day 11, at which time concentrations 
remained consistently above 100% until the bottle was 
emptied on day 14. On days 0, 5 and 10, when data from 
all four time points were analyzed, branded prednisolone 
concentrations were lowest at the first time point and peaked 
at the third or fourth time point; each of these data series 
showed substantial intraday variability, with day 5 containing 
both the lowest (20.5%) and the highest (181.4%) concentra-
tions. The generic prednisolone acetate concentrations were 
the most varied of all the steroid preparations, ranging from 
7.0% to 231.5% of declared concentration. Most time points 
prior to day 13 were less than 100% of declared concentration, 
whereas each time point at day 14 and beyond was greater 
than 100%, ranging from 123.6% to 231.5%.
When upright bottles were shaken slowly for five seconds 
prior to dispensing, difluprednate emulsion concentrations 
were consistently near 100% of declared concentration, with 
the range of concentrations varying 8.1% (Figure 2). The 
branded prednisolone acetate suspension concentrations were 
primarily higher than 100% of the declared concentration, with 
the initial concentration 312.0% of declared concentration; 
only two data points were below 100%, but the lowest 
reached only 51.0% of declared concentration. In contrast, 
generic prednisolone acetate concentrations were primarily 
below 100% through day 14, with most time points below 
70% of declared concentration. From day 15 and beyond, 
only three time points were below 100%, with concentra-
tions on the final two days spiking to 504.6% of declared 
concentration.
Figure 3 illustrates that the inverted bottle of difluprednate 
emulsion, not shaken prior to dispensing, approximated 
declared concentration throughout the study, with a high 
of 103.5% and a low of 96.2%. The branded prednisolone 
acetate suspension produced concentrations above the 
declared concentration (up to 201.4%) for the first two days, 
after which concentrations dropped below 100%, with values 
ranging from 80.1% to 10.7% of declared concentration. 
The generic prednisolone acetate suspension followed a 
similar pattern, with most time points in the first three days 
far above 100% of declared concentration, after which they 
dropped far below 100%. None of the time points for the 
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final 10 days of the experiment reached greater than 20% of 
declared concentration.
As shown in Table 2, difluprednate emulsion concentration 
remained within 15% of declared concentration at each time 
point analyzed and under all conditions tested. In contrast, 
branded prednisolone acetate suspension concentrations 
met this criterion for 54% of the upright and not shaken 
time points and 40% of the upright and shaken time points. 
None of the prednisolone acetate concentrations from the 
inverted bottle was within 15% of declared concentration. 
Generic prednisolone acetate concentrations were within 
15% of declared concentration for only 4%–13% of the time 
points, depending on the condition tested. Measurement of 
drug concentrations within 10% of declared concentration 
remained nearly identical for difluprednate emulsion, with 
only one datum point from the upright and not shaken bottle 
outside this range (98% of the data points were within 
10% of declared concentration). One hundred percent of 
concentrations analyzed from the other two diflupred-
nate bottles were within 10% of declared concentration. 
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Figure 2 Dose uniformity of difluprednate emulsion and prednisolone acetate suspensions with upright storage orientation after 5 seconds of shaking of contents.
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Branded prednisolone acetate concentrations within 10% 
of declared concentration were 34% for the upright and not 
shaken bottle, 23% for the upright and shaken bottle, and 
0% for the inverted bottle. Generic prednisolone acetate 
concentrations within 10% of declared concentration were 
4% for the upright and not shaken bottle, 6% for the upright 
and shaken bottle, and 0% for the inverted bottle.
Discussion
This study compared two corticosteroid suspensions with 
a corticosteroid formulated in an emulsion. Suspensions 
have a well characterized tendency to settle, agglomerate, 
and recrystallize over time, all of which reduce dispersion 
homogeneity and allow potential dosing inconsistencies. 
One approach to reduce these dosing errors is to shake the 
contents prior to use in an attempt to redisperse the drug; 
another approach is to formulate the drug as an emulsion 
rather than a suspension. Emulsions are produced by 
dissolving the active drug molecule within the oil phase of 
the formulation. Emulsions also contain a surfactant, which 
acts as a stabilizer, preventing the oil droplets from   coalescing 
and allowing aqueous compatibility.6 Thus, emulsions create 
homogeneous dispersions that are not subject to sedimenta-
tion or aggregation. Empirically, emulsions have been shown 
to produce greater ocular bioavailability than suspensions, 
as demonstrated by a pharmacokinetic study conducted in 
rabbits, in which a corticosteroid emulsion showed a 4.1-fold 
higher area under the curve (AUC) in aqueous humor and a 
4.6-fold higher AUC in cornea than the same corticosteroid 
formulated as a suspension.7 A similar relationship between 
emulsion and suspension formulations was reported by 
Inoue et al in another pharmacokinetic animal study, in which 
the corticosteroid emulsion produced an aqueous humor 
concentration that was 40% higher than the corticosteroid 
suspension.8
The current study illustrates the predictability in dose 
uniformity of difluprednate ophthalmic emulsion 0.05% 
compared with prednisolone acetate suspension 1%. Regard-
less of the simulated patient usage conditions (upright versus 
inverted storage, shaking prior to use versus no shaking), 
difluprednate remained near 100% of declared concentration 
with little variability. Only one datum point was not within 
10% of declared concentration, and this was likely an outlier, 
as evidenced by the fact that the other 40 data points from this 
testing condition were within 4.2% of declared concentration. 
These results were reproduced in multiple additional runs 
conducted under similar conditions using other difluprednate 
lots (data not shown). In contrast, both branded and generic 
prednisolone acetate suspensions varied substantially in all 
three simulated patient usage conditions, with none of them 
showing consistent approximation of declared concentration. 
Concentrations from the branded prednisolone acetate bottle 
stored upright with no shaking prior to use varied consider-
ably throughout the study, alternating between very high 
and low concentrations. Even prednisolone acetate drops 
dispensed on the same day differed dramatically, with the 
largest variability exhibited on day 5, ie, 20.5% at the first 
time point compared with 181.4% at the last time point. 
Concentrations from the generic prednisolone acetate bottles 
demonstrated the largest variability, ranging from 224.5% 
for the upright and not shaken bottle to 720.8% for the 
inverted bottle.
The dose uniformity of difluprednate can be attributed to 
its emulsion formulation. Because the concentration of drug 
throughout the bottle is consistent, it is not subject to bottle 
storage orientation. Moreover, difluprednate emulsion does 
not require shaking of the contents in order to resuspend 
the drug within its vehicle. In contrast, prednisolone acetate 
is required to be shaken prior to use because of its poor 
homogeneity upon storage.5 In the current study, however, 
shaking the prednisolone acetate bottles, either branded or 
generic, prior to dispensing did little to improve the dose 
uniformity, as shown in Figure 2. In this data set, only 40% 
of the time points from the branded prednisolone and 6% 
from the generic prednisolone had concentrations within 
15% of declared concentration. Of interest is the difference 
in the effect of shaking between the branded prednisolone and 
generic prednisolone products. Overall, very low concentra-
tions in the generic prednisolone bottle were observed through 
day 15, while the branded product exhibited overall higher 
concentrations with much less variability. In most cases, a 
lower dispensed drug concentration of generic prednisolone 
was observed on the first dose of each day compared with 
the final dose of each day. This suggests that with enough 
agitation, the generic prednisolone will eventually disperse 
uniformly in the bottle. It is possible that the type, intensity, 
or duration of the mechanical shaking performed in this study 
was not adequate to resuspend the drug fully, but this cannot 
Table  2  Percentage  of  data  points  within  15%  of  declared 
concentration
Usage condition Pred Forte® Durezol® Generic  
prednisolone
Upright, not shaken 54% 100% 13%
Upright, shaken 40% 100% 6%
inverted, not shaken 0% 100% 4%Clinical Ophthalmology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal
Clinical Ophthalmology is an international, peer-reviewed journal 
covering all subspecialties within ophthalmology. Key topics include: 
Optometry; Visual science; Pharmacology and drug therapy in eye 
diseases; Basic Sciences; Primary and Secondary eye care; Patient 
Safety and Quality of Care Improvements. This journal is indexed on 
PubMed Central and CAS, and is the official journal of The Society of 
Clinical Ophthalmology (SCO). The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1124
Stringer and Bryant
be evaluated because no studies have been published that 
determine optimal shaking parameters. Nonetheless, these 
results suggest that the effect of shaking on the resuspension 
of prednisolone acetate should be further evaluated.
The inverted bottles of prednisolone acetate, which 
were not shaken prior to use, demonstrated the greatest 
concentration variability of all suspension bottles tested. 
Initially, both the branded and generic prednisolone acetate 
concentrations from the inverted bottles were greater than the 
declared concentration. However, by day 3, concentrations 
rapidly dropped below declared concentration, not reaching 
above 50% of declared concentration for the final 10 days 
of either suspension. This pattern of dose variability 
(increased concentrations at early time points followed by 
low concentrations later) is consistent with settling occurring 
within the tip of the bottle, allowing for highly concentrated 
drops to be dispensed initially until the majority of the drug 
has been depleted from the bottle, resulting in little drug 
dispensed at later time points. The discrepancy between the 
dose variability of prednisolone acetate suspension in this 
study and the dose uniformity exhibited by difluprednate 
emulsion suggests that the clinical use of difluprednate may 
produce more predictable efficacy and safety.
Conclusion
The dose uniformity of difluprednate ophthalmic emulsion 
0.05% was highly predictable in all simulated patient usage 
conditions, confirming that this product is not dependent 
on bottle shaking. The drop concentration of both branded 
and generic prednisolone acetate suspension 1% was 
highly variable over the duration of the study and across 
patient usage conditions. Shaking did not improve the dose 
uniformity of these products.
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